Key result
Two older men developed Guillain-Barré syndrome approximately three weeks after experiencing symptoms of SARS-CoV-2 infection, highlighting a potential delayed immune-mediated neurologic complication.
Why the study?
Does therapeutic plasma exchange improve bradycardia unresponsive to atropine in a patient with severe COVID-19 and Guillain-Barré syndrome?
Case Report (n=2)
No
Does therapeutic plasma exchange improve bradycardia unresponsive to atropine in a patient with severe COVID-19 and Guillain-Barré syndrome?
Answers are grounded in this paper and cite their sources.
Therapeutic plasma exchange successfully treated atropine-refractory bradycardia in a patient with severe COVID-19 and Guillain-Barré syndrome.
Bradycardia unresponded to atropin testing was successfully treated with therapeutic plasma exchange in a patient with severe COVID-19 complicated by Guillain-Barré syndrome: A case report,
No takes yet. Share an insight, caveat, or question.
Chan et al. (2020) conducted a case report in Guillain-Barré Syndrome after COVID-19 (n=2). SARS-CoV-2 infection was evaluated. Two older men developed Guillain-Barré syndrome approximately three weeks after experiencing symptoms of SARS-CoV-2 infection, highlighting a potential delayed immune-mediated neurologic complication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: